ESRRB and breast carcinoma: We therefore tested the capacity of the ERRβ/γ agonist DY131 to modulate breast cancer and non-transformed mammary epithelial cell growth, as measured by crystal violet staining (Figure 2A, Supplementary Figure S1A).